Neurosense Therapeutics Ltd(NRSN)

0.7201+0.0001+0.01%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Neurosense Therapeutics Achieves Primary Endpoint in Phase 2B ALS Study
  Reuters · 06-29 22:34
  Neurosense Therapeutics Achieves Primary Endpoint in Phase 2B ALS Study
- Neurosense Rises as Nerve Disease Drug Shows Promise in Study
  Reuters · 06-29 21:51
  Neurosense Rises as Nerve Disease Drug Shows Promise in Study
- NeuroSense says Phase 2b PARADIGM study of PrimeC in ALS met endpoint
  TIPRANKS · 06-29 21:35
  NeuroSense says Phase 2b PARADIGM study of PrimeC in ALS met endpoint
- Neurosense Says Phase 2b ALS Trial Meets Primary Endpoint, Cuts Tdp-43 vs Placebo (p=0.0421)
  Reuters · 06-29 21:30
  Neurosense Says Phase 2b ALS Trial Meets Primary Endpoint, Cuts Tdp-43 vs Placebo (p=0.0421)
- Neurosense Achieves Primary Endpoint in Phase 2B ALS Study with Statistically Significant Reduction of Tdp-43, the Defining Pathological Hallmark of ALS
  THOMSON REUTERS · 06-29 21:30
  Neurosense Achieves Primary Endpoint in Phase 2B ALS Study with Statistically Significant Reduction of Tdp-43, the Defining Pathological Hallmark of ALS
- Neurosense Therapeutics - Primec Shows Favorable Safety Profile with no New Safety Signals over 18 Months
  THOMSON REUTERS · 06-29 21:30
  Neurosense Therapeutics - Primec Shows Favorable Safety Profile with no New Safety Signals over 18 Months
- Neurosense Reports Positive Biomarker Findings from Phase 2 Road Proof-of-concept Study of Primec in Alzheimer's Disease
  THOMSON REUTERS · 06-25
  Neurosense Reports Positive Biomarker Findings from Phase 2 Road Proof-of-concept Study of Primec in Alzheimer's Disease
- NeuroSense joins EverythingALS community event on PrimeC data in ALS
  Reuters · 06-22
  NeuroSense joins EverythingALS community event on PrimeC data in ALS
- NeuroSense CEO Alon Ben-Noon acquires 250,000 shares worth USD 200,000
  Reuters · 06-18
  NeuroSense CEO Alon Ben-Noon acquires 250,000 shares worth USD 200,000
- Neurosense Therapeutics - Granted South Korean Patent Covering Primec Composition for ALS
  THOMSON REUTERS · 06-11
  Neurosense Therapeutics - Granted South Korean Patent Covering Primec Composition for ALS
- NeuroSense wins South Korean patent for PrimeC ALS drug composition through 2042
  Reuters · 06-11
  NeuroSense wins South Korean patent for PrimeC ALS drug composition through 2042
- Roth MKM Keeps Their Buy Rating on Neurosense Therapeutics Ltd. (NRSN)
  TIPRANKS · 06-10
  Roth MKM Keeps Their Buy Rating on Neurosense Therapeutics Ltd. (NRSN)
- NeuroSense secures Japan patent for PrimeC ALS drug formulation through 2042
  Reuters · 06-09
  NeuroSense secures Japan patent for PrimeC ALS drug formulation through 2042
- NeuroSense meets Health Canada on PrimeC regulatory pathway for ALS drug submission
  Reuters · 06-08
  NeuroSense meets Health Canada on PrimeC regulatory pathway for ALS drug submission
- NeuroSense prices $600,000 private placement at $0.8 per share
  Reuters · 04-29
  NeuroSense prices $600,000 private placement at $0.8 per share
- Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Eton Pharmaceuticals (ETON) and Ligand Pharma (LGND)
  TIPRANKS · 04-27
  Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Eton Pharmaceuticals (ETON) and Ligand Pharma (LGND)
- NeuroSense announces departure of Chief Medical Officer
  TIPRANKS · 04-27
  NeuroSense announces departure of Chief Medical Officer
- NeuroSense CMO Ferenc Tracik steps down, effective April 27
  Reuters · 04-24
  NeuroSense CMO Ferenc Tracik steps down, effective April 27
- NeuroSense wins Brazil patent for PrimeC composition, extending protection to 2042
  Reuters · 04-06
  NeuroSense wins Brazil patent for PrimeC composition, extending protection to 2042
- NeuroSense gets Nasdaq notice for breaching $1 minimum bid price requirement
  Reuters · 04-03
  NeuroSense gets Nasdaq notice for breaching $1 minimum bid price requirement
Company Profile
Company Name
Neurosense Therapeutics Ltd
Market
NASDAQ
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.neurosense-tx.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
- 03-31
  Annual Report
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2025-11-25
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2025-08-15
  Employee Stock Ownership
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 2025-04-07
  Annual Report
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2025-01-16
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2025-01-06
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2024-12-13
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2024-12-09
  Beneficial Ownership Change
  Form SC 13G - Statement of Beneficial Ownership by Certain Investors
  Form SC 13G - Statement of Beneficial Ownership by Certain Investors
- 2024-11-22
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2024-11-19
  Public Prospectus
  Form F-1 - Registration statement for certain foreign private issuers
  Form F-1 - Registration statement for certain foreign private issuers
- 2024-05-21
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2024-05-20
  [Amend]Public Prospectus
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
- 2024-05-10
  Public Prospectus
  Form F-1 - Registration statement for certain foreign private issuers
  Form F-1 - Registration statement for certain foreign private issuers
- 2024-04-04
  Annual Report
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2024-02-13
  Beneficial Ownership Change
  Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
  Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

1D
5D
Day
Week
Month

Loading ...

High

0.7222

Open

0.7200

Volume%

0.13

Low

0.7200

T/O Rate

0.01%

To The Moon

Neurosense Therapeutics Ltd(NRSN)

Company Profile

Most Discussed